CA3024719A1 - Treatment of pain - Google Patents

Treatment of pain Download PDF

Info

Publication number
CA3024719A1
CA3024719A1 CA3024719A CA3024719A CA3024719A1 CA 3024719 A1 CA3024719 A1 CA 3024719A1 CA 3024719 A CA3024719 A CA 3024719A CA 3024719 A CA3024719 A CA 3024719A CA 3024719 A1 CA3024719 A1 CA 3024719A1
Authority
CA
Canada
Prior art keywords
compound
par2
endosomal
signaling
inhibits
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3024719A
Other languages
English (en)
French (fr)
Inventor
Nigel BUNNETT
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Endosome Therapeutics Inc
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2016901912A external-priority patent/AU2016901912A0/en
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Publication of CA3024719A1 publication Critical patent/CA3024719A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Botany (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
CA3024719A 2016-05-20 2017-05-19 Treatment of pain Pending CA3024719A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2016901912 2016-05-20
AU2016901912A AU2016901912A0 (en) 2016-05-20 Treatment of Pain
PCT/AU2017/050469 WO2017197463A1 (en) 2016-05-20 2017-05-19 Treatment of pain

Publications (1)

Publication Number Publication Date
CA3024719A1 true CA3024719A1 (en) 2017-11-23

Family

ID=60324618

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3024719A Pending CA3024719A1 (en) 2016-05-20 2017-05-19 Treatment of pain

Country Status (9)

Country Link
US (1) US20190298743A1 (https=)
EP (1) EP3458062A4 (https=)
JP (3) JP2019516734A (https=)
CN (1) CN109152777A (https=)
AU (3) AU2017268039A1 (https=)
CA (1) CA3024719A1 (https=)
EA (1) EA201892672A1 (https=)
MX (2) MX395658B (https=)
WO (1) WO2017197463A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA202091524A1 (ru) * 2017-12-20 2020-09-16 Такеда Фармасьютикал Компани Лимитед Ингибиторы рецептора, активируемого протеазой 2
US20240066027A1 (en) 2020-12-03 2024-02-29 Domain Therapeutics Novel par-2 inhibitors
KR20250057699A (ko) 2022-06-03 2025-04-29 도메인 테라퓨틱스 신규한 par-2 억제제
WO2025172573A1 (en) 2024-02-16 2025-08-21 Domain Therapeutics Combinations of par2 inhibitors and immune checkpoint inhibitors for the treatment of cancer
WO2025191185A1 (en) 2024-03-15 2025-09-18 Domain Therapeutics Azine-based compounds as par-2 inhibitors and therapeutic uses thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL106998A0 (en) * 1992-09-17 1993-12-28 Univ Florida Brain-enhanced delivery of neuroactive peptides by sequential metabolism
US7541156B1 (en) * 2000-03-01 2009-06-02 Pasricha Pankaj J Method of identifying antinociceptive compounds using protease activated receptor-2
CN1938013A (zh) * 2003-11-21 2007-03-28 纽卡斯尔大学研究协会有限公司 抑制发动蛋白依赖性的细胞内摄作用的方法和药剂
US20070225363A1 (en) * 2003-11-21 2007-09-27 The University Of Newcastle Research Associates Ltd. Methods and Agents for Inhibiting Dynamin-Dependent Endocytosis
JP4896870B2 (ja) * 2004-04-08 2012-03-14 ヤード・テヒノロギース・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 細胞膜ラフトと相互作用する構造を含む三者複合体およびその使用
EP2119455A1 (en) * 2004-04-08 2009-11-18 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Tripartite raftophilic structures and their use
WO2009034464A2 (en) * 2007-09-12 2009-03-19 Newcastle Innovation Limited Indole related compounds with physiological activity
AR070911A1 (es) * 2008-03-19 2010-05-12 Regeneron Pharma Uso de antagonistas del receptor par2 activado con proteasa
WO2013010218A1 (en) * 2011-07-15 2013-01-24 Freie Universität Berlin Inhibition of clathrin
HK1223096A1 (zh) * 2013-09-25 2017-07-21 Vertex Pharmaceuticals Incorporated 用作par-2信號通路抑制劑的咪唑並噠嗪
CN115531553A (zh) * 2015-12-22 2022-12-30 武田药品工业株式会社 内体g蛋白-偶联的受体的三部分调节剂
AT518095B1 (de) * 2015-12-30 2018-01-15 Univ Wien Tech Verfahren zur Herstellung von ionischen Flüssigkeiten auf Basis des Bistriflimid-Anions
EA202091524A1 (ru) * 2017-12-20 2020-09-16 Такеда Фармасьютикал Компани Лимитед Ингибиторы рецептора, активируемого протеазой 2

Also Published As

Publication number Publication date
JP2022061998A (ja) 2022-04-19
NZ788380A (en) 2025-07-25
EP3458062A1 (en) 2019-03-27
JP7441246B2 (ja) 2024-02-29
JP2024073450A (ja) 2024-05-29
MX395658B (es) 2025-03-26
AU2023201732A1 (en) 2023-04-20
CN109152777A (zh) 2019-01-04
JP2019516734A (ja) 2019-06-20
EP3458062A4 (en) 2020-01-15
MX2022011564A (es) 2023-06-15
EA201892672A1 (ru) 2019-04-30
AU2025202933A1 (en) 2025-05-15
NZ748579A (en) 2025-07-25
AU2017268039A1 (en) 2018-12-06
MX2018014135A (es) 2019-06-17
US20190298743A1 (en) 2019-10-03
WO2017197463A1 (en) 2017-11-23

Similar Documents

Publication Publication Date Title
AU2023201732A1 (en) Treatment of pain
US20230119819A1 (en) Tripartite Modulators of Endosomal G Protein-Coupled Receptors
MXPA03011331A (es) Tratamiento del dolor mediante el direccionamiento de canales se abren por un nucleotido ciclico, activado mediante hiperpolarizacion.
KR102543227B1 (ko) 폐고혈압을 치료하기 위한 병용 요법
US6677376B1 (en) Non-peptidic cyclophilin binding compounds and their use
US20200383985A1 (en) Inhibitors of Protease Activated Receptor-2
EP3373947B1 (en) Compounds and methods for treating pain
BR112018012425B1 (pt) Composto tripartido, e, composição farmacêutica
US20200206299A1 (en) Inhibitors of beta-arrestin-neurokinin 1 receptor interactions for the treatment of pain

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220518

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20240807

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20241206

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250205

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 8TH ANNIV.) - STANDARD

Year of fee payment: 8

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250515

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250515

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250605

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250605

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250918

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251127